Sarcoidosis Treatment Guidelines

Introduction to Sarcoidosis Treatment

• The European Respiratory Society recommends glucocorticoids as the first-line treatment for symptomatic sarcoidosis with risk of mortality or permanent disability, with methotrexate recommended as the preferred second-line agent when glucocorticoids are ineffective or cause unacceptable side effects 1, 2, 3

Treatment Algorithm Based on Disease Severity

• For symptomatic pulmonary sarcoidosis with high risk of mortality or permanent disability, initial therapy with prednisone 20 mg once daily for 2-6 weeks is recommended, followed by maintenance with 5-10 mg daily or every other day, with monitoring of bone density, blood pressure, and serum glucose 1, 2
• For patients with continued disease or unacceptable side effects from glucocorticoids, adding methotrexate 10-15 mg once weekly can improve/preserve lung function and quality of life 1, 2, 4
• Alternative second-line agents for pulmonary sarcoidosis include azathioprine, leflunomide, or mycophenolate mofetil 2, 3
• For cardiac sarcoidosis, glucocorticoids with or without other immunosuppressives are strongly recommended for patients with functional cardiac abnormalities, with consideration of early initiation of steroid-sparing medications due to significant morbidity of long-term glucocorticoid use 5, 6
• For neurosarcoidosis, first-line treatment is glucocorticoids, with second-line treatment being the addition of methotrexate if disease continues despite glucocorticoids, and third-line treatment being the addition of infliximab if disease continues despite glucocorticoids and second-line agents 7
• For cutaneous sarcoidosis, infliximab can be considered for patients with continued active skin disease despite glucocorticoids/immunosuppressives, with alternative treatment being hydroxychloroquine 200-400 mg once daily with periodic ocular exams 2, 7, 8
• For sarcoidosis-associated fatigue, first-line treatment is a pulmonary rehabilitation program and/or inspiratory muscle strength training for 6-12 weeks, with second-line treatment being consideration of D-methylphenidate or armodafinil for 8 weeks to test effect on fatigue and tolerability 8, 9

Important Considerations

• Monitoring treatment response should include assessment of improvement in symptoms, pulmonary function tests, and radiographic findings, with specific monitoring for cardiac sarcoidosis including left ventricular ejection fraction and brain natriuretic peptide, and for fatigue including evaluation of functional improvement with 6-minute walk test 1, 6, 9
• Treatment duration should be based on response to treatment, with continuation of therapy for 3-6 months providing rationale for continuing therapy, and at least half of patients started on glucocorticoids remaining on treatment 2 years later 1
• Inhaled glucocorticoids added to oral glucocorticoids do not provide significant benefits, and there is no data on mortality balance between benefits from long-term treatment and risks due to treatment-induced comorbidities 1
• Risk stratification should prioritize patients at risk for mortality or permanent disability, with specific risk factors for cardiac sarcoidosis including age >50 years, left ventricular ejection fraction <40%, ventricular tachycardia, and cardiac inflammation on imaging, and for pulmonary sarcoidosis including pulmonary hypertension, reduced lung function, and pulmonary fibrosis 6, 10

Cellcept Dosing for Sarcoidosis

Dosing Algorithm

• The European Respiratory Society recommends dosing mycophenolate mofetil (Cellcept) at 500-1500 mg twice daily (total daily dose 1000-3000 mg) for sarcoidosis, with monitoring of complete blood count 11, 12, 13, 14, 15
• Start at 1000 mg twice daily (2000 mg total daily dose) and titrate based on response and tolerability, according to the European Respiratory Society guidelines 11, 12, 13, 14, 15
• The therapeutic range extends from 500 mg twice daily up to 1500 mg twice daily, as recommended by the European Respiratory Society 11, 12, 13, 14, 15

Clinical Context and Evidence Quality

• The European Respiratory Society guidelines note that mycophenolate mofetil has "less experience in sarcoidosis than other agents" compared to methotrexate, azathioprine, or leflunomide 11, 12, 13, 14, 15

Monitoring Requirements

• Complete blood count (CBC) should be monitored regularly to detect leukopenia, as recommended by the European Respiratory Society 11, 12, 13, 14, 15
• Monitor for primary toxicities: diarrhea, leukopenia, infections, and potential malignancy risk, according to the European Respiratory Society guidelines 11, 12, 13, 14, 15

Response Assessment

• Allow 3-6 months to assess therapeutic response before concluding treatment failure, as recommended by the European Respiratory Review 16

Key Clinical Pitfalls

• The European Respiratory Society guidelines designate mycophenolate mofetil as having "less experience" and recommend preferring methotrexate as the first steroid-sparing agent unless specific contraindications exist 11, 12, 13, 14, 15
• Do not discontinue mycophenolate mofetil prematurely, allow adequate time (3-6 months minimum) to assess response, as recommended by the European Respiratory Review 16